Synthetic data — demonstration only. No real patient information.

This is what your oncologists could be receiving.

A 487-page NGS report for a metastatic NSCLC adenocarcinoma case (EGFR L858R · TP53 co-mutation · PD-L1 <1%) — compressed into a 2-page Actionable Insight in 1.4 seconds. Toggle between the oncologist's view and the raw API response.

EGFR L858RTP53 R175H co-mutationPD-L1 <1%Stage IVA NSCLC487 source pages1.4s processing time
Download sample PDF

UNMIRI

Actionable Insight Report

ID: ins_demo_8xk2mq9p

April 18, 2026 — 09:14:32 UTC

Page 1 of 2

Patient

ID: DEMO-2026-001
Age / Sex: 67 · Female
Diagnosis: Metastatic NSCLC Adenocarcinoma
Stage: Stage IVA (T2a N3 M1b)
Specimen: CT-guided core biopsy — right lower lobe
Platform: FoundationOne CDx (482-gene panel)

Biomarkers

PD-L1 (22C3)

<1%

TMB

4.2 mut/Mb

MSI

MSI-Stable

Actionable Alterations

EGFR L858R

Actionable
Exon 21VAF 34.2%Point mutation

Pathogenic — sensitizing

TP53 R175H

Exon 5VAF 41.1%Point mutation

Pathogenic — co-occurring

Negative findings (selected)

ALK rearrangement — negative

ROS1 rearrangement — negative

MET exon 14 skipping — not detected

RET fusion — negative

+3 more — see source report

Treatment Recommendations — Evidence-graded

OncoKB 2026-Q1 · openFDA · FLAURA NEJM 2018

1

Osimertinib (Tagrisso®)

3rd-gen EGFR TKILevel 1FDA-approved (2018, first-line)

EGFR exon 21 L858R sensitizing mutation. FLAURA trial: OS 38.6 mo vs. 31.8 mo for 1st-gen TKI. OncoKB Level 1 evidence; FDA-approved first-line (2018).[C1][C2]

Dosing: 80 mg orally once daily

2

Erlotinib + Ramucirumab

1st-gen EGFR TKI + VEGFR2 inhibitorLevel 2AFDA-approved

RELAY trial: PFS 19.4 vs. 12.4 months. Consider in EGFR L858R with TP53 co-mutation where osimertinib resistance is anticipated.[C1][C3]

Dosing: Erlotinib 150 mg PO daily + Ramucirumab 10 mg/kg IV q14d

3

Carboplatin + Pemetrexed ± Bevacizumab

Platinum doublet chemotherapyLevel 2BFDA-approved

Reserve for EGFR TKI-ineligible patients or acquired resistance. TP53 R175H co-mutation may predict earlier TKI resistance; platinum doublet remains a viable second-line option.[C1]

Dosing: Carboplatin AUC 5 + Pemetrexed 500 mg/m² IV q21d

Contraindication — High Priority

Checkpoint Inhibitor Monotherapy

Drugs affected: Pembrolizumab · Atezolizumab · Cemiplimab

PD-L1 TPS <1% (Dako 22C3 pharmDx). EGFR-mutant NSCLC demonstrates poor response to PD-1/PD-L1 inhibitors independent of PD-L1 expression. Concurrent use with EGFR TKI associated with excess pulmonary toxicity (TATTON trial). Checkpoint inhibitor monotherapy not indicated.[C1][C4]

Generated by UNMIRI GraphRAG v1.2 · 487 source pages → 2 pages · 1380ms

Not for clinical use without physician review · Continue →

Page 1 of 2

What you just saw

Every element of this output is grounded in structured knowledge — not LLM inference.

📊

Evidence-graded recommendations

Each recommendation carries an OncoKB evidence level and FDA-approval status — the same sources your oncologists reference manually.

⚠️

Contraindication flagging

The PD-L1 <1% + EGFR mutation combination triggers a high-priority checkpoint inhibitor contraindication — automatically, from the knowledge graph.

🔬

Clinical trial matching

MARIPOSA-2 surfaced because 3 of 3 eligibility criteria match. The graph traverses variant → trial eligibility — not keyword search.

📋

Full citation trail

Every recommendation links back to the OncoKB entry, FDA label, and trial citation that supports it. Auditable on demand.

Ready to generate reports like thisfor your lab?

This report was generated from a synthetic dataset in 1.4 seconds via a single REST API call. Your NGS volume, your LIMS, your oncologist clients. Applications open for the Q2 2026 pilot cohort.

Apply for a Pilot SlotHow the engine works →

All data on this page is synthetic. No real patient information was used.